MedPath

XYWAV

These highlights do not include all the information needed to use XYWAV safely and effectively. See full prescribing information for XYWAV. XYWAV (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIIIInitial U.S. Approval: 2002

Approved
Approval ID

1e0ae43a-037f-42af-8e23-a0e51d75abe8

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 25, 2023

Manufacturers
FDA

Jazz Pharmaceuticals, Inc.

DUNS: 135926363

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

(calcium, magnesium, potassium, and sodium oxybates)

PRODUCT DETAILS

NDC Product Code68727-150
Application NumberNDA212690
Marketing CategoryC73594
Route of AdministrationORAL
Effective DateMarch 10, 2022
Generic Name(calcium, magnesium, potassium, and sodium oxybates)

INGREDIENTS (4)

SODIUM OXYBATEActive
Quantity: 0.5 g in 1 mL
Code: 7G33012534
Classification: ACTIB
Calcium OxybateActive
Quantity: 0.5 g in 1 mL
Code: 8W24SYD6ZI
Classification: ACTIB
Potassium OxybateActive
Quantity: 0.5 g in 1 mL
Code: S8NKF3H3KT
Classification: ACTIB
Magnesium OxybateActive
Quantity: 0.5 g in 1 mL
Code: G983HLV265
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.